$heff's $tation of $tocks & $olid DD

[$heff]

Brief $heff Summary on 9/21..Patience..is the name of the game in my personal opinion with most of these play! That is what has worked for me & many on the board. My avg time holding a stock is anywhere from 1-4 months and in a few cases longer. Go to my trades and take a look for yourself. The quick flip nets smaller profits but the ones at least 4 weeks out do well. Does not mean I won't flip for a 20% or 30% gain in a few days but that does not happen frequently. That is what works for me and where I see the money is made with these big board biotechs. Money comes into them it is just a matter of when.

AEZS..$.87 was a perfect example of one that just stayed under %.50 for the longest time then started a solid upward trend closing above $.80 yesterday. Was a good play at $.46 to $.92. Closed position.

HEB..$.93 will be a solid play as the catalysts are in place & the company has support from the FDA. The market makers & flippers will play with this one above $.90 until they decide to let it go & it will go. Inexperience will get shaken out & patience will persevere IMO. At least CFS is being recognized now and given the attention it deserves. In 2009 that was not the case & HEB was the laughing stock of the biotech field. It deserved to get a CRL that it did when it did. The key is the company does not have to do another Phase III study as originally instructed from FDA. There NDA was accepted with additional data to be reviewed. That is a plus in itself. In 2012 the FDA recognizes CFS as an unmet need & wants to better understand surrogate endpoints & issues from the patient perspective. This is where the accelerated approval process can potentially be a benefit for them. The FDA is dedicating time & resources to better understanding the disease to bring a treatment to market. I will add on pullbacks under $.90. https://federalregister.gov/a/2012-22874

ZGNX..$2.70 has had a nice move the past week after struggling to break $2.40. The volume has steadily increased & this looks to be a solid play. Been in since $2.33

RPTP..$5.37 will gradually move higher into their PDUFA date of Jan 30th. They are in the rare ultra-orpan drug space. Been in since $4.88.

CYTK..$.90 finally broke $.90 but it took a while. Q4 should be good for them. Been in since $.70

ACAD..$2.66 has been an absolute beast and I have been in since June with $1.50 avg. Continue to hold my shares as this one has a strong catalyst at end of November.

Looking at other plays to add near-term.

As always..just my own personal thoughts & observations here.